Industry
Biotechnology
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Loading...
Open
0.96
Mkt cap
2.6M
Volume
824K
High
0.96
P/E Ratio
0.02
52-wk high
134.68
Low
0.85
Div yield
N/A
52-wk low
0.30
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 1:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 1:40 pm
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 1:40 pm
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
October 18, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 3:44 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 12:49 pm
Portfolio Pulse from Benzinga Insights
October 14, 2024 | 12:09 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.